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The increase in life expectancy in the Brazilian population raises questions about 
the preparation of the public health system in identifying elderly patients with 
signs of cognitive impairment. Currently, as a consequence of the long duration 
of preclinical phase of Alzheimer’s disease, efforts of early detection have been 
emphasized. Clinical dementia presents an important impact on the individual’s 
caregivers, family, society and economy. Identifying individuals who already have 
some cognitive impairment, despite remaining functional, as well as analyzing 
associated comorbidities, constitutes an opportunity to analyze possibilities for 
future interventions. Dementias are clinical conditions that impose a burden 
on the health system with its high costs, whereas the identification of individuals 
with cognitive impairment without dementia can aid patients and their families 
to plan the future and mitigate costs. This narrative revision can provide general 
practitioners with more information on the subject.
Keywords: elderly, cognitive deficits, mild cognitive impairment, general practice, 
Alzheimer’s disease, diagnosis.
introduction
In the last decades, Brazil has undergone rapid demo-
graphic transition with an increase in the population of 
elderly. The Brazilian life expectancy has reached 73 years 
and, currently, the elderly represent approximately 10% 
of the general population. In 2030, they will be 36%.1,2
Along with the aging of the global population, there 
is an increase in the incidence and prevalence of diseases 
associated with senility including mild cognitive impair-
ment (MCI) or, according to DSM-5, mild neurocognitive 
disorder.3 Subjects aged 60 years or older with subjective 
cognitive complaints corroborated by an informant show 
an increased conversion rate to MCI or to dementia.4 The 
risk of elderly individuals with subjective cognitive com-
plaints to progress to MCI or dementia is 1.5 to 3 higher 
than in those without it.5 According to Petersen et al.6 the 
annual conversion rate of amnestic-type MCI to clinical 
dementia ranges from 10 to 15%. 
The term “mild cognitive impairment” was first sug-
gested in 1980 by Reisberg et al.7 The first paper on MCI was 
published in 1994 by Petersen;8 but only in 1999 Petersen et 
al.6 further developed the concept by proposing criteria 
based on an observational study on ageing. The concept of 
MCI defines an early but abnormal stage of cognitive harm, 
no longer considered a normal part of aging, and therefore 
a diagnostic entity and pathological condition. The initial 
criteria were: a) subjective impairment of the memory, pref-
erentially confirmed by an informant; b) objective impairment 
of the memory compared with a group paired by age and 
education level (below 1.5 standard deviations from the 
mean); c) normal global cognitive functioning; d) indepen-
dence in daily life activities; and e) absence of dementia. This 
concept is based on the observation that Alzheimer’s 
disease (AD) progresses insidiously, usually initiating with 
a memory deficit that is well characterized, and may allow 
the diagnosis of AD in the phase of pre-dementia.9
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At a Key Symposium held in Stockholm in the year 2003, 
MCI was defined as a heterogeneous entity divided into three 
categories: amnestic MCI with greater risk of AD; MCI of 
multiple cognitive domains; and MCI with impairment of a 
single cognitive function different from memory.10 Main 
diagnostic points of MCI were redefined: the individual be-
ing neither normal nor demented; evidence of cognitive 
decline measured objectively or based on subjective perception 
combined with objective cognitive impairment; preservation 
of basic living and complex instrumental activities or mini-
mally compromised.10 A task force of American authorities, 
led by the National Institute of Aging and the Alzheimer’s 
Association, proposed a review of the criteria used for the 
classification of MCI in 2011.11 Despite the basic clinical 
criteria being similar to those for MCI diagnosis, this review 
opened the focus on the probable etiological mechanisms 
that lead to cognitive impairment, with emphasis on early 
diagnosis of AD, via the utilization of biomarkers.
The term “mild cognitive disorder” was included in 
the International Classification of Diseases (ICD) to be 
applied to patients that presented a decline in cognitive 
performance, usually accompanied by abnormalities in 
objective tests for cognitive functions, but not sufficient-
ly to fulfill the diagnostic criteria of dementia.12 
epideMiology
The first population-based study on the prevalence of 
MCI and its subtypes (Figure 1)13 was based on a cardio-
vascular health study.14 The researchers applied the cri-
teria for MCI retrospectively in a cohort and found a 
prevalence of 22%, of which 6% referred to the amnestic 
subtype and 16% to multiple domains in patients aged 
65 years or older.15 Other studies demonstrated an inci-
dence rate from 1 to 6% per year and a prevalence of 3 to 
22%.15 The prevalence and incidence of MCI found in 
Brazil was similar to rates observed in other countries.16 
In a riverside-dwelling population with low education 
and practically no vascular risk factors, MCI prevalence 
was 7.7%.17 A systematic review and meta-analysis on the 
prevalence of dementia among individuals aged 60 years 
or older found a narrow range of 5-7% in most world 
regions, with a higher prevalence in Latin America (8.5%), 
and a distinctively lower prevalence in the four sub-Sa-
haran African regions (2-4%).18 In this study, 35.6 million 
people lived with dementia worldwide in 2010, with num-
bers expected to almost double every 20 years, to 65.7 
million in 2030 and 115.4 million in 2050. Yet, in 2010, 
58% of all people with dementia lived in countries with 
low or middle incomes, with this proportion expected to 
rise to 63% in 2030 and 71% in 2050.18    
progression to ad (figure 2)19
Several authors observed an increased rate of progression 
toward dementia in patients with MCI.8,20-25 However, stud-
ies have not been replicated by other researchers. One ex-
planation for this fact may arise from the observation that 
memory complaints appear to have little correlation with 
the performance of individuals on objective cognitive tests.26
On the other hand, longitudinal studies revealed that 
elderly individuals with recent complaints of impaired 
memory performed worse in memory tests than those 
who had not had such a complaint in one year of follow-
-up. They suggest that memory complaints from the el-
derly must be taken even more seriously when accompa-
nied by objective signals of cognitive deterioration.27,28 
Despite some discrepancies among studies, the research-
ers agree that individuals diagnosed with MCI develop 
dementia at a faster rate than the rest of the population. 
evaluation of MeMory proBleMs
The initial evaluation must rely on careful obtainment of 
patient history and of memory complaint, always compar-
ing to previous functional state of cognitive complaint,29 
establishing a chronology for the initiation of symptoms, 
as well as habits and comorbidities; investigation of mood 
symptoms and behavioral alterations. Questions on dietary 
and sleep habits must be posed.30,31 Detailed neurological 
and general physical exam must be carried out, with thor-
ough observation of gait and verification of motor signals 
(alterations of reflexes, rigidity, bradykinesia, tremor, slow-
ness).32 The laboratory exams that must be performed to 
rule out reversible dementia syndromes include:
 • Thyroid hormone tests to investigate underacti-
ve thyroid. 
 • Vitamin B12 blood test to check vitamin deficiency. 
 • Complete blood count to investigate infections. 
 • Aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) blood tests that check liver function. 
 • Chemistry screening to check the level of electroly-
tes in the blood and to check kidney function. 
 • Glucose test to check the level of sugar in the blood. 
 • VDRL and HIV. 
 • Erythrocyte sedimentation rate, a blood test that in-
vestigates signs of inflammation in the body. 
 • Toxicology screening, examining blood and urine. 
 • Antinuclear antibodies, a blood test used to diagno-
se autoimmune diseases. 
 • Investigation of heavy metals in the blood, such as a 
lead test.33 
 • A lumbar puncture to test for certain proteins in the 
spinal fluid. 
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FIGURE 1 Current algorithm used to classify the subtypes of mild cognitive impairment (MCI).
Source: Petersen R.13
FIGURE 2 Charting the Course from Healthy Ageing to AD.
MCI: mild cognitive impairment; AD: Alzheimer’s disease.
Source: National Institute On Aging – NIH.
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Neuroimaging exams must be requested, including 
CT or MRI scans, not only to verify the limbic structures 
but also to rule out other diseases, particularly vascular 
cognitive impairment.34
Screening tests such as the mini-exam of the mental 
state,35 clock-drawing test, verbal fluency and a question-
naire on instrumental and basic daily life activities, as 
well as the geriatric depression scale (GDS) questionnaire, 
must be applied.36,37
neuropsychological testing
Longitudinal studies investigating the usefulness of neu-
ropsychological tests to identify subjects at high risk of 
developing dementia reported that, by measuring recall, 
delayed recall, verbal fluency and visual-motor skill, they 
were able to identify 85% of the individuals that developed 
dementia and 95% of those that remained stable, in four 
years of accompaniment.23 The results suggest that indi-
viduals with increased risk of developing dementia, or in 
a preclinical state of AD, can be identified by neuropsy-
chological tests, which evaluate mainly memory (measures 
of late evocation) and other cognitive functions, such as 
attention, language and thought.23 The standardized 
application of tests to elderly individuals with cognitive 
complaints is a manner of rendering the concept of cog-
nitive impairment both valid and reliable.38
neuroiMaging
In the initial stages of the disease, cranial MRI might not 
present abnormalities. In some cases, a SPECT or PET 
scan can be considered.30 In SPECT a decline in blood 
flow is noted whereas in PET a reduction of glucose uti-
lization is observed. PIB and FDG PET are employed in 
some research studies to compare controls with patients 
suffering from AD and MCI.39
treatMent
Currently, there is no evidence for the utilization of drugs 
for the treatment of individuals with MCI.40 Nonetheless, 
several clinical trials have been conducted in an attempt 
to slow down the appearance of dementia.41 There was a 
large clinical trial involving 70 medical centers in North 
America.42 The study was randomized, double-blind and 
placebo-controlled and aimed to verify the safety and 
efficacy of vitamin E (2,000 IU per day) and donepezil (10 
mg per day). A decrease, although not significant, was 
noted in the conversion rate of MCI to AD from 45 to 
30% in a three-year period. Among 769 randomized indi-
viduals, the annual conversion rate of MCI to AD was 
approximately 16%. Donepezil reduced the risk of AD in 
the first 12 months of the trial, but there was no drop in 
the progression to AD in 36 months. Vitamin E had no 
therapeutic effect.43
conclusion
Aging of the population is making the cases of chronic de-
generative diseases more frequent, including AD. In MCI, a 
loss of memory for recent facts with relative preservation of 
functionality is observed. A general practitioner must know 
that individuals with MCI constitute a group of great risk 
for AD. Early identification of individuals in the beginning 
of clinical dementia provides a possibility of intervening in 
the progression of the disease and providing support to 
patients and their family members. Upon encountering el-
derly patients with memory complaints, the physician must 
perform a detailed anamnesis and complete physical exam, 
ruling out reversible causes of cognitive alterations. Mood 
symptoms such as depression and anxiety, if identified, need 
to be treated. Laboratory exams must include a complete 
blood count, fasting blood glucose, electrolytes, renal, liver 
and thyroidal function, lipidogram, folic acid and vitamin 
B12. An imaging exam such as cranial CT or MR should also 
be performed. Cognitive testing must include a mini-exam 
of the mental state (mini-mental), clock-drawing test and 
verbal fluency for fruits and animals. The Brazilian Public 
Health System (SUS, in the Portuguese acronym) is respon-
sible for a great portion of patient healthcare in the country. 
The Family Health Team of Basic Health Units must serve 
as both the first contact and the longitudinal contact with 
SUS users, enabling the recognition of the patients’ cognitive 
impairment and potential progression to AD.
resuMo
Comprometimento cognitivo leve e progressão para a 
demência da doença de Alzheimer
O aumento da expectativa de vida da população brasileira 
faz surgir questões sobre o preparo do sistema de saúde 
pública na identificação de pacientes idosos com sinais de 
alteração cognitiva. Atualmente, como consequência da 
longa duração da fase pré-clínica da doença de Alzheimer 
(DA), existe maior ênfase sobre a detecção precoce. A de-
mência apresenta um importante impacto sobre a família, 
os cuidadores, a sociedade e a economia. Identificar indi-
víduos que já apresentam algum comprometimento cog-
nitivo, embora eles mantenham a funcionalidade, bem 
como analisar as comorbidades associadas constituem 
oportunidades para direcionar futuras intervenções. De-
mências são doenças que impõem sobrecarga ao sistema 
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público de saúde, com altos custos. A identificação de 
indivíduos com alteração cognitiva sem demência pode 
adicionar planejamentos futuros por parte do próprio 
doente, da sua família e dos cuidadores, resultando em 
menor sobrecarga física e emocional para todos os envol-
vidos. Esta revisão narrativa tem como objetivo ajudar os 
clínicos gerais a atuar na detecção dos idosos que se en-
contram em risco de desenvolver demência.
Palavras-chave: idoso, déficit cognitivo, comprometi-
mento cognitivo leve, clínico geral, doença de Alzheimer, 
diagnóstico.
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